RESEARCH MONOGRAPH · KDC-MN-251

Pregabalin

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 3 min read

Our opinion on this compound

81/100

Workhorse alpha-2-delta ligand with cleaner kinetics than gabapentin and a real abuse profile people undersell

Pregabalin is the gabapentin successor that Pfizer designed to fix the bioavailability mess of its older cousin, and on that narrow goal they succeeded. Saturable transport via LAT1 was the killer feature missing from gabapentin; pregabalin binds the same alpha-2-delta-1 subunit of voltage-gated calcium channels but with linear pharmacokinetics across the clinically relevant range. That single design improvement is the whole reason it took over.

The mechanism is well-mapped at this point. Binding to the alpha-2-delta-1 auxiliary subunit reduces calcium influx at presynaptic terminals, which dampens release of glutamate, substance P, and noradrenaline in hyperexcitable circuits. It's not a GABA-mimetic despite the name; it doesnt touch GABA receptors directly. The GABA analog label is a structural artifact, not a functional one, and that confusion still shows up in textbooks.

What we like is the cleanness of the human evidence. Multiple phase 3 trials in fibromyalgia, neuropathic pain, generalized anxiety, partial seizures. The effect sizes are modest but reproducible, which is more than most CNS compounds can say. Onset is faster than SSRIs for anxiety, which makes it useful as a research probe for state vs trait anxiety dissociation.

What we dont like is how the medical community soft-pedaled the abuse liability. Pregabalin has clear euphoriant effects at supratherapeutic doses, particularly when stacked with opioids, and the UK rescheduling to class C in 2019 was overdue. The withdrawal syndrome is real and looks more like benzodiazepine taper than people initially appreciated. As a research compound you should know that going in.

Sourcing is straightforward. It's an off-patent small molecule with global generic production, and HPLC verification is standard. The S-enantiomer is the active one, so racemic preparations are a red flag.

Reliability is high for what it is. Pregabalin does what it says on the tin. The interesting research questions are mostly about whether alpha-2-delta-1 binding explains the full clinical picture (probably not, given how thrombospondin interactions modulate synaptogenesis) and whether the related subunit alpha-2-delta-2 contributes more than we currently model. Still a useful tool.

Evidence: 90
Mechanism: 82
Reliability: 85
Safety: 65
Sourcing: 88
Value: 80
Signal: 75
Staying power: 80

Plain-language summary Intrigue 67 / 100

Pregabalin (Lyrica) is a GABA look-alike that does not actually bind any GABA receptor or GABA transporter. Instead it binds the alpha-2-delta subunit of voltage-gated calcium channels, which reduces the release of glutamate and several other neurotransmitters at synapses. The compound came out of Northwestern University and was developed by Pfizer; the FDA approved it in 2004. It is widely used for neuropathic pain (diabetic neuropathy, postherpetic neuralgia), fibromyalgia, partial seizures, and generalized anxiety. Onset is rapid by anxiolytic standards (within hours to a few days). It produces euphoria in some patients and is a Schedule V controlled substance in the US owing to abuse potential, particularly in people with prior opioid or sedative use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Alpha-2-delta calcium channel ligand (GABA analog)

A GABA structural analog binding the alpha-2-delta subunit of voltage-gated calcium channels; approved for neuropathic pain, fibromyalgia, and partial seizures.

Abstract

Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid; CAS 148553-50-8; molecular formula C8H17NO2; molecular weight 159.23) is a GABA structural analog developed at Pfizer (Northwestern University origin, Lipton/Silverman) and approved by the FDA in 2004 under the trade name Lyrica. Despite the structural resemblance to GABA, the compound does not act on GABA-A, GABA-B, or GABA reuptake mechanisms; the molecular target is the alpha-2-delta-1 subunit of voltage-gated calcium channels, where high-affinity binding (Ki approximately 22 nM) reduces presynaptic calcium influx and consequent release of glutamate, norepinephrine, substance P, and CGRP. Plasma half-life is 6.3 hours; renal excretion is the principal clearance pathway with linear pharmacokinetics. Approved indications include neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures (adjunctive), and generalized anxiety disorder (in EU). The compound has scheduled status (Schedule V in the US) reflecting modest abuse potential at supratherapeutic doses, where users report euphoria and benzodiazepine-like effects. Used as the canonical alpha-2-delta calcium channel ligand reference.

Mechanism of action

Alpha-2-delta-1 subunit binding on voltage-gated calcium channels; reduces presynaptic neurotransmitter release. No direct GABA receptor activity despite structural resemblance.

Reported research dose ranges

Clinical 75 to 600 mg per oral administration daily, in divided doses. Rodent studies 5 to 100 mg/kg/day.

References

Field MJ, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci 2006.
Tassone DM, et al. Pregabalin: a novel gamma-aminobutyric acid analogue. Clin Ther 2007.
Hauser P, Devinsky O. The pharmacokinetics of pregabalin and its therapeutic applications. Curr Neurol Neurosci Rep 2007.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-251 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Pregabalin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs